Besides the different expression levels and signaling transduction patterns of LPAR1 in different tumors, another significant reason for the controversy around LPAR1’s function or failed clinical trials of LPAR1 antagonists is the mutations of LPAR1 in cancer tissues. Here, LPAR1 is linked to cancer.